December 27, 2006
Charter Pacific Corporation Limited acquires the business of Opus Media
Charter Pacific Corporation Limited (ASX code: CHF) has acquired the business of UK based company, Opus...
December 20, 2006
ChemGenex Appoints Dr Denis Wade To Board Of Directors
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (December 20, 2006). ChemGenex Pharmaceuticals...
December 11, 2006
ChemGenex Investigators Report Activity of Ceflatonin� and Gleevec� Combination Therapy in CML Patients Resistant to Gleevec� Alone
Positive Phase 2 Data Presented at American Society of Hematology Meeting, MELBOURNE, Australia,...
November 22, 2006
ChemGenex Appoints Dr Ian Nisbet as Vice-President of Oncology
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (November 22, 2006). ChemGenex Pharmaceuticals...
November 15, 2006
ChemGenex Announces Granting of Fast Track Status for Ceflatonin� by FDA
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (November 15, 2006). ChemGenex Pharmaceuticals...
September 20, 2006
Initial Patients Treated in Multinational Phase 2/3 Study of ChemGenex’s Ceflatonin�
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (September 20, 2006). ChemGenex Pharmaceuticals...
September 12, 2006
Business expansion after year of consolidation
Listed investment company, Charter Pacific Corporation (ASX:CHF) said today that it expected the company’s...
August 25, 2006
BOARD OF DIRECTORS
Mr Bryan Dart, Non-Executive Director, has resigned from the Board of Directors, effective as at the...
August 22, 2006
Financial Services Fund launched as part of Charter Pacific Expansion
An innovative financial services investment fund to be managed by two former QIC (Queensland Investment...
August 15, 2006
ChemGenex Pharmaceuticals Limited Newsletter
ChemGenex Pharmaceuticals Limited, 18.6% owned by Charter Pacific, has released a newsletter for shareholders.
August 2, 2006
ChemGenex Announces Publication Of Two New Clinical Studies Supporting
Expanded Opportunity For Ceflatonin� Beyond CML To Other Leukemias MELBOURNE, Australia, and MENLO PARK, California U.S.A. (August 2, 2006)ChemGenex Pharmaceuticals...
August 2, 2006
Monteray executes licence agreement for its GPen system
Monteray announced today that a non-exclusive licence agreement has been executed with an Australian...
July 26, 2006
Response To Questions Arising From Media Coverage Of Heart Failure Linked To Gleevec�
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (July 26, 2006). Over the past 24 hours there...
June 26, 2006
ChemGenex Teams with MolecularMD to Identify CML Patients with the T315I Drug Resistance Mutation for Phase 2/3 Clinical Trial of Ceflatonin� MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 26, 2006). ChemGenex Pharmaceuticals (ASX:...
June 19, 2006
ChemGenex Investigators Present Data at European Hematology Association Meeting Showing Success of Ceflatonin for Treating CML Patients Resistant to Gleevec�
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 19, 2006). ChemGenex Pharmaceuticals Limited...
June 15, 2006
Patersons Note on ChemGenex
Patersons has prepared a note on ChemGenex Pharmaceuticals Limited.
June 14, 2006
ChemGenex Media Coverage
ChemGenex Pharmaceuticals announced yesterday the new international trials for its anti-cancer drug.
June 13, 2006
ChemGenex Launches Multinational Phase 2/3 Study for CML Patients with the T315I Mutation Reports Preclinical activity in T315I CML
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 13, 2006). ChemGenex Pharmaceuticals (ASX:...
June 8, 2006
ChemGenex Discovery Highlighted At International Diabetes Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 8, 2006). ChemGenex Pharmaceuticals (ASX:...
June 6, 2006
ChemGenex To Present At Pacific Growth Equities 2006 Life Sciences Growth Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (June 6, 2006). ChemGenex Pharmaceuticals (ASX:...
May 16, 2006
ABN Amro Note on ChemGenex
Amro Morgans has prepared a note on ChemGenex Pharmaceuticals Limited 16 May 2006.
May 11, 2006
ChemGenex To Present At Rodman & Renshaw 3rd Annual Global Healthcare Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 11, 2006). ChemGenex Pharmaceuticals (ASX:...
May 8, 2006
ChemGenex Completes $A15 Million Capital Raising
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (May 8, 2006). ChemGenex Pharmaceuticals Limited...
April 4, 2006
Preclinical Progress Reported at American Association of Cancer Research Conference
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (April 4, 2006). ChemGenex Pharmaceuticals Limited...
March 23, 2006
New Preclinical Research Supports Ceflatonin� in Treatment of Acute Myeloid Leukemia (AML)
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (March 23, 2006). ChemGenex Pharmaceuticals...
March 20, 2006
Orphan Drug Designation Granted by the U.S. FDA for Ceflatonin�
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (March 20, 2006). ChemGenex Pharmaceuticals...
March 6, 2006
Cowen & Co 26th Annual Health Care Conference to Webcast ChemGenex Presentation
Monteray Group Limited (ASX: MRY) today announced its intention to acquire 100 per cent of global pensions...
February 23, 2006
MONTERAY ACQUISITION OF GPEN
Monteray Group Limited (ASX: MRY) today announced its intention to acquire 100 per cent of global pensions...
January 18, 2006
ChemGenex Granted U.S. Patent on Ceflatonin�’s Use for Treatment of Gleevec�-Resistant Patients with CML and Ph-Positive ALL
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (January 18, 2006): ChemGenex Pharmaceuticals...
January 17, 2006
New Diabetes Research Contract With Merck KGaA
MELBOURNE, Australia, and MENLO PARK, California U.S.A. (January 17, 2006): ChemGenex Pharmaceuticals...